# Notice of rescheduled AGM

RNS Number : 8954C
Novacyt S.A.
15 June 2023

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Notice of rescheduled AGM

AGM to be held in Paris on Thursday 10 August

Paris, France and Eastleigh, UK - 15 June 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's Annual General Meeting (AGM), due to take place earlier today, will be rescheduled and held in person in Paris on Thursday 10 August at 1pm BST/2pm CEST.

To function as a procedural meeting, the AGM requires a sufficient number of shareholder votes to constitute a quorum to ensure the AGM is validly held in accordance with French corporate law. This threshold has not been met, therefore, in accordance with Article 19 of Novacyt articles of association, the AGM has been rescheduled.

The rescheduled AGM will be an open meeting exclusively, held in The Hilton Hotel, Paris Charles De Gaulle Airport, and will also be streamed online for those shareholders wishing to join virtually. The agenda will remain the same as in the first convening and the AGM will comprise of both ordinary and extraordinary resolutions.

Shareholders can register to view the AGM via the online meeting platform by visiting www.novacytagm23.eventcaster.co.uk.

Forms of Proxy already completed and submitted and votes cast by electronic means for the first AGM remain valid for all meetings subsequently convened with the same agenda (art. R. 225-77 of the French commercial code). Full details of dates concerning voting will follow in due course.

Contacts

| | |
|---|---|
| Novacyt SA | +44 (0)23 8074 8830 |
| James Wakefield, Non-Executive Chairman<br>James McCarthy, Acting Chief Executive Officer | |
| | |
| SP Angel Corporate Finance LLP (Nominated Adviser and Broker) | +44 (0)20 3470 0470 |
| Matthew Johnson / Charlie Bouverat (Corporate Finance)<br>Vadim Alexandre / Rob Rees (Corporate Broking) | |
| | |
| Numis (Joint Broker) | +44 (0)20 7260 1000 |
| Freddie Barnfield / Duncan Monteith / Jack McLaren | |
| | |
| Allegra Finance (French Listing Sponsor)<br>Rémi Durgetto / Yannick Petit | +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com |
| | |
| Walbrook PR (Financial PR & IR)<br>Stephanie Cuthbert / Anna Dunphy / Phillip Marriage | +44 (0)20 7933 8780<br>novacyt@walbrookpr.com |

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAZZGMVDKZGFZM